Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 4/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16989567 | 0.86 | USP2 (0.43) | ELANEUSP2SMN1; SMN2HDAC1NR1H2 | |
| SCHEMBL17009070 | 0.80 | ELANE (0.40) | ELANEUSP2SMN1; SMN2HDAC1NR1H2 | |
| SCHEMBL1931528 | 0.77 | ELANE (0.38) | ELANEUSP2SMN1; SMN2ESR2MAPK1 | |
| SCHEMBL428501 | 0.76 | HDAC1 (0.44) | USP2SMN1; SMN2HDAC1NR1H2ESR2 | |
| SCHEMBL2674926 | 0.75 | ESR2 (0.42) | SMN1; SMN2ESR2KDM4EMAPTMAPK1 | |
| SCHEMBL16995873 | 0.75 | USP2 (0.43) | USP2SMN1; SMN2HDAC1NR1H2ADORA1 | |
| SCHEMBL424707 | 0.74 | ESR2 (0.43) | USP2SMN1; SMN2NR1H2ADORA1ESR2 | |
| SCHEMBL31037749 | 0.74 | ELANE (0.36) | ELANE | |
| SCHEMBL424756 | 0.74 | ESR2 (0.43) | USP2SMN1; SMN2NR1H2ADORA1ESR2 | |
| SCHEMBL424706 | 0.74 | ESR2 (0.43) | USP2SMN1; SMN2NR1H2ADORA1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11155532-B2 | Cyclopropylamines as LSD1 inhibitors | INCYTE CORPORATION (US) | 2021-10-26 | — | — | US | disclosed |
| US-20210024487-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | INCYTE CORPORATION | 2021-01-28 | — | — | US | disclosed |
| US-10676457-B2 | Cyclopropylamines as LSD1 inhibitors | INCYTE CORPORATION (US) | 2020-06-09 | — | — | US | disclosed |
| EP-3626714-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | Incyte Corporation (US) | 2020-03-25 | — | — | EP | disclosed |
| EP-3105226-B1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | INCYTE CORP (US) | 2019-09-04 | — | — | EP | disclosed |
| US-9994546-B2 | Cyclopropylamines as LSD1 inhibitors | INCYTE CORPORATION (US) | 2018-06-12 | — | — | US | disclosed |
| US-20170121302-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | INCYTE CORPORATION | 2017-05-04 | — | — | US | disclosed |
| US-9493450-B2 | Cyclopropylamines as LSD1 inhibitors | INCYTE CORPORATION (US) | 2016-11-15 | — | — | US | disclosed |
| US-20150225394-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | INCYTE CORPORATION (US) | 2015-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10676457-B2 | Cyclopropylamines as LSD1 inhibitors | KDM1B, KDM1A, KDM2A | ELANE 4631/4885USP2 422/4885SMN1; SMN2 2689/4885 |
| US-20210024487-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM2A | ELANE 4631/4885USP2 422/4885SMN1; SMN2 2689/4885 |
| US-20170121302-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM2A | ELANE 4631/4885USP2 422/4885SMN1; SMN2 2689/4885 |
| US-11155532-B2 | Cyclopropylamines as LSD1 inhibitors | KDM1B, KDM1A, KDM2A | ELANE 4631/4885USP2 422/4885SMN1; SMN2 2689/4885 |
| US-20150225394-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM2A | ELANE 4631/4885USP2 422/4885SMN1; SMN2 2689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.